Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use

Astellas Pharma said on August 18 that the US FDA has accepted for review its nonhormonal agent fezolinetant for the treatment of vasomotor symptoms (VMS) associated with menopause, known as hot flashes or night sweats. The drug is eligible for...read more